Brief: Talaris Therapeutics Announces Initiation Of Phase 2 Clinical Trial Of FCR001 For Severe Form Of Scleroderma
Brief: Talaris Therapeutics Announces Third Quarter 2021 Financial Results And Provides Business Update
Brief: Talaris Therapeutics Initiates Phase 2 Clinical Trial Of FCR001 In Delayed Tolerance Induction
Brief: Talaris Therapeutics Announces Q2 Loss Per Share Of $0.41
Brief: Talaris Therapeutics Announces Q1 Loss Per Share Of $1.30
Brief: Talaris Therapeutics Shares Open At A Premium of 1.5% In Nasdaq Debut Vs IPO Price
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM
Brief: Talaris Therapeutics Announces Pricing Of Initial Public Offering
Brief: Talaris Sees IPO Of Up To 8.83 Million Shares Priced $16 To $18 Per Share